Evidence map›Paper›PMID 38833113›Full record

ArticleInternational journal of clinical oncology2024

Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.

Kenji Tanabe, Shuichiro Kobayashi, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto, Sho Uehara and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kenji TanabeDepartment of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan.
Shuichiro KobayashiDepartment of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan. shu_kobayashi@saitama-med.jrc.or.jp.ORCID http://orcid.org/0009-0000-7290-1826
Yuya MaezawaDepartment of Urology, Tsuchiura Kyodo General Hospital, 1-1-4 Otsuno, Tsuchiura-shi, Ibaraki, 300-0028, Japan.
Kensaku IshiharaDepartment of Urology, Soka Municipal Hospital, 1-21-2 Soka, Soka-shi, Saitama, 340-8560, Japan.
Naoki InoueDepartment of Urology, JA Toride Medical Hospital, 1-1-2 Hongo, Toride-shi, Ibaraki, 302-0022, Japan.
Keita IzumiDepartment of Urology, Dokkyo Medical University Saitama Medical Center, 50-1-2 Minamikoshigaya, Koshigaya-shi, Saitama, 343-8555, Japan.
Motohiro FujiwaraDepartment of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Masahiro ToideDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 22-18-3 Honkomagome, Bunkyo-ku, Tokyo, 131-8677, Japan.
Takanobu YamamotoDepartment of Urology, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, 2-1-2 Nakazawa, Tama-shi, Tokyo, Japan.
Sho UeharaDepartment of Urology, Showa General Hospital, 1-1-8 Hanakoganei, Kodaira-shi, Tokyo, Japan.
Saori ArakiDepartment of Urology, Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa-shi, Chiba, 272-8516, Japan.
Masaharu InoueDepartment of Urology, Saitama Prefectural Cancer Center, 780 Oaza-Komuro, Kitaadachi-gun-Ina-machi, Saitama, 362-0806, Japan.
Ryoji TakazawaDepartment of Urology, Tokyo Metropolitan Ohtsuka Hospital, 1-8-2 Minamiohtsuka, Toshima-ku, Tokyo, Japan.
Noboru NumaoDepartment of Urology, Cancer Institute Hospital, 31-8-3 Ariake, Koto-ku, Tokyo, Japan.
Yukihiro OhtsukaDepartment of Urology, Japanese Red Cross Omori Hospital, 1-30-4 Chuo, Ota-ku, Tokyo, Japan.
Hajime TanakaDepartment of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Soichiro YoshidaDepartment of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Yasuhisa FujiiDepartment of Urology, Tokyo Medical and Dental University, 45-5-1 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab.

methodsThis multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model.

resultsDuring the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both p < 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both p < 0.001), presence of visceral metastasis (both p < 0.001), and hemoglobin of < 9.2 g/dL (p = 0.030 and p = 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (p = 0.001).

conclusionThe GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab.

Indexed as

Antibodies, Monoclonal, HumanizedAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalBiomarkers, TumorCarcinoma, Transitional CellDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedNeutrophilsPrognosisProgression-Free SurvivalRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiomarkers, TumorpembrolizumabImmune checkpoint inhibitorsMetastasisPrognosisTransitional cell carcinoma

Identifiers

PMID38833113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.